Cover Image
市場調查報告書

次發性副甲狀腺機能亢進 : 開發平台分析

Secondary Hyperparathyroidism - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 253669
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
次發性副甲狀腺機能亢進 : 開發平台分析 Secondary Hyperparathyroidism - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 38 Pages
簡介

次發性副甲狀腺機能亢進是由於鈣的顯著低下造成副甲狀腺過度分泌副甲狀腺素(PTH)的狀態,有骨骼變形、骨折、關節腫脹、慢性腎臟衰竭等症狀。治療方法有鈣受體激動劑及荷爾蒙補充療法等。

本報告涵括全球次發性副甲狀腺機能亢進治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

次發性副甲狀腺機能亢進概要

治療藥的開發

  • 次發性副甲狀腺機能亢進開發中產品:概要
  • 次發性副甲狀腺機能亢進開發中產品:比較分析

次發性副甲狀腺機能亢進:正在開發的治療藥:各企業

次發性副甲狀腺機能亢進:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

次發性副甲狀腺機能亢進:開發中的產品:各企業

次發性副甲狀腺機能亢進:開發治療藥的企業

  • Amgen Inc.
  • Deltanoid Pharmaceuticals Inc.
  • 田邊三菱製藥
  • Nektar Therapeutics
  • OPKO Health, Inc.

次發性副甲狀腺機能亢進:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Calcifediol MR
  • Calcimimetic-18
  • CTA-091
  • CTAP-201
  • DP-001
  • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney 疾病 and Cancer
  • etelcalcetide
  • lunacalcipol
  • MT-4580
  • NKTR-228
  • VS-105
  • VS-110
  • VS-411
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9538IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H2 2017, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 3 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Secondary Hyperparathyroidism - Overview
    • Secondary Hyperparathyroidism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Secondary Hyperparathyroidism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Deltanoid Pharmaceuticals Inc
    • Mitsubishi Tanabe Pharma Corp
    • OPKO Health Inc
    • Shire Plc
  • Secondary Hyperparathyroidism - Drug Profiles
    • cinacalcet hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTA-091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • evocalcet - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Secondary Hyperparathyroidism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Secondary Hyperparathyroidism - Dormant Projects
  • Secondary Hyperparathyroidism - Discontinued Products
  • Secondary Hyperparathyroidism - Product Development Milestones
    • Featured News & Press Releases
      • Jun 23, 2017: Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara (cinacalcet) For The Treatment Of Secondary Hyperparathyroidism In Certain Children With End-Stage Renal Disease On Dialysis
      • Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan
      • Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
      • Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
      • Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
      • Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
      • Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg
      • Mar 07, 2013: Health Canada Cautions Against Use Of Amgen's Sensipar In Children
      • Feb 26, 2013: Amgen's Pediatric Clinical Trial Of Sensipar Suspended By FDA Following Death Of Patient
      • Nov 03, 2012: Amgen Announces Results From Phase III EVOLVE Trial Of Sensipar/Mimpara In Patients With Secondary Hyperparathyroidism And Chronic Kidney Disease Receiving Dialysis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Secondary Hyperparathyroidism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H2 2017
  • Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017
  • Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H2 2017
  • Secondary Hyperparathyroidism - Pipeline by Shire Plc, H2 2017
  • Secondary Hyperparathyroidism - Dormant Projects, H2 2017
  • Secondary Hyperparathyroidism - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Secondary Hyperparathyroidism, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top